Maximizing Start-up Opportunities with Patient Advocacy Foundations
In the heat of looking for funding from traditional sources such as VCs, start-ups often overlook opportunities for additional funds from Patient Advocacy Groups. Foundations certainly serve as a potential source for seed grants and clinical trial support, especially for companies whose technology targets a specific disease. However, patient advocacy foundations can also provide other resources, including critical access to experts and databases of patients for clinical trials. Foundations understand nuances of the target population that are important to making a clinical trial successful, such as disease natural history, and can provide important advocacy to regulators.
- What drives the investing decisions of foundations?
- How can entrepreneurs better define their goals in approaching foundations in order to maximize the opportunity for support at crucial time points of growth, such as early stage-funding or during an exit?
- What does “success” look like for both parties
- Steps to evolve the relationship between the parties to ensure continued commitment?
Join us for an illuminating conversation around partnering with foundations from the perspective of both the entrepreneur and the foundation and learn how working with a foundation may benefit your company.
Senior Commercialization Officer
PATH is a global health organization that leverages diagnostics, drugs, and vaccine technologies to propagate global health initiatives, PATH is one of largest funding recipient of the Bill and Melinda Gates Foundation (BMGF), receiving over $200M per year. Prior to joining PATH, he was senior vice president, corporate development at Kineta, Seattle, WA (2008-2014) a biotechnology company focused on early clinical development. During his tenure he provided strategic direction for funding, partnering and commercial development. He helped raise over $52 Million in the initial funding efforts, sourcing funds from government grants, foundations, private investors and family offices. Mr. Cadwallader also served as Vice President of Business development at Velcura, Therapeutics; Ann Arbor, MI. (2007-2008); From (2004 to 2007), Mr. Cadwallader was the Vice-President of Marketing and Strategic Planning at Cell Therapeutics, a publically traded bio-pharma company. He was responsible for sales and commercialization activities for both solid and liquid tumor programs. From 1984 to 2004, Mr. Cadwallader held various management position of increasing responsibility in product development, marketing and global and commercial planning of Oncology, CV & Metabolic franchises at Amgen, Parke-Davis/Sankyo and Pharmacia Upjohn. Mr. Cadwallader holds a BA in Marketing from Eastern Washington University and an MBA from Seattle University.
Bruce Markham, PhD
President & CEO
Diapin Therapeutics LLC
Bruce Markham is President and CEO at Diapin Therapeutics. In addition, Bruce Markham is also Chief Scientific Officer at Phrixus Pharmaceuticals in Ann Arbor, and serves on the advisory board of Cytometix. He previously served as mentor-in-residence in the Office of Technology Transfer at the University of Michigan and as a drill instructor at the Ann Arbor SPARK entrepreneurial boot camp. Prior to Diapin and Phrixus, he was a research fellow at Pfizer and Parke-Davis in the cardiovascular area, where he brought several compounds to the clinical candidate stage, was a member of the Cardiovascular Licensing Team, the Global PPAR team and led the Heart Failure and Hypertension Disease teams. He was an Associate Professor of physiology at the Medical College of Wisconsin, as well as an Established Investigator at the American Heart Association. Dr. Markham received his B.A. degree from Western Michigan University and his PhD degree from Michigan State University. He received his post-doctoral training in molecular genetics and cardiovascular physiology at the University of Arizona.
BioArbor hosts educational networking events for the life sciences industry in the greater Ann Arbor area. BioArbor's focus is on technology commercialization, financing strategies, business development, regulatory affairs, and marketing. Each monthly meeting features a networking session and an invited speaker, followed by a Q&A period. Invited speakers share experience on topics such as drug discovery and development, medical devices, diagnostics, and tools. BioArbor events are open to the public and are especially suited for those interested in starting or growing life science businesses.